Elranatamab for Multiple Myeloma
Trial Summary
What is the purpose of this trial?
This trial is testing Elranatamab, a drug that helps the immune system target and kill cancer cells, in patients with a type of blood cancer that hasn't responded to other treatments. The drug works by connecting immune cells to cancer cells so they can be destroyed.
Do I need to stop my current medications for the trial?
The trial information does not specify if you need to stop taking your current medications. However, it mentions that you should not have taken an investigational drug within 30 days before starting the trial.
What data supports the effectiveness of the drug Elranatamab for treating multiple myeloma?
Elranatamab has shown promising results in treating multiple myeloma, with a study reporting a 63.6% response rate and 38.2% of patients achieving complete response or better. The drug was effective even in patients who had received prior treatments, with a median duration of response of 17.1 months and manageable safety profile.12345
Is Elranatamab safe for humans?
In a clinical trial for multiple myeloma, Elranatamab was found to have manageable safety with no dose-limiting toxicities observed. Some patients experienced side effects like low blood cell counts (cytopenias) and a reaction called cytokine release syndrome, but these were considered manageable.12467
What makes the drug Elranatamab unique for treating multiple myeloma?
Elranatamab is unique because it is a bispecific antibody that targets both BCMA on myeloma cells and CD3 on T cells, activating the T cells to attack the cancer cells. It is administered subcutaneously and has shown promising results in patients who have already undergone multiple other treatments, including those who have had prior BCMA-directed therapy.12489
Research Team
Pfizer CT.gov Call Center
Principal Investigator
Pfizer
Eligibility Criteria
This trial is for adults with multiple myeloma who haven't responded to at least one proteasome inhibitor (PI), one immunomodulatory drug (IMiD), and one anti-CD38 antibody. Participants should have measurable disease, be in stable condition, not pregnant, willing to use contraception, and without other active cancers or serious infections. There are two groups: those who've had BCMA-targeted therapy before and those who haven't.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Elranatamab monotherapy to evaluate clinical benefit in relapsed/refractory multiple myeloma
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term follow-up
Participants are monitored for progression-free survival and overall survival
Treatment Details
Interventions
- Elranatamab (PF-06863135)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Pfizer
Lead Sponsor
Albert Bourla
Pfizer
Chief Executive Officer since 2019
PhD in Biotechnology of Reproduction, Aristotle University of Thessaloniki
Patrizia Cavazzoni
Pfizer
Chief Medical Officer
MD from McGill University